Abalos Therapeutics grabs Series A
Abalos Therapeutics, a German cancer drug developer, has raised 12 million euros in Series A financing. Boehringer Ingelheim Venture Fund and Gruenderfonds Ruhr led the round.
15 October 2019•1 min read
Abalos Therapeutics, a German cancer drug developer, has raised 12 million euros in Series A financing. Boehringer Ingelheim Venture Fund and Gruenderfonds Ruhr led the round.
